Brief: U.S. FDA Gives Green Light To Molecure's Flagship Program
July 24 (Reuters) - Molecure SA MOCP.WA :
* U.S. FOOD AND DRUG ADMINISTRATION GIVES GREEN LIGHT TO
MOLECURE'S FLAGSHIP PROGRAM - PHASE II CLINICAL TESTING OF
OATD-01 IS READY FOR LAUNCH
* MOLECURE SA - FIRST PULMONARY SARCOIDOSIS PATIENTS IN THIS
PHASE
II STUDY ARE SCHEDULED TO BEGIN RECEIVING TREATMENT IN Q4 2O23
* MOLECURE SA - EXPECT TO CONCLUDE PHASE II CLINICAL STUDIES
IN
MID-2025 WITH PUBLICATION OF A REPORT ANALYZING HEADLINE DATA
Source text for Eikon: ID:nGNX6lNnhH
Further company coverage: MOCP.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Molecure SA
See all newsBrief: Molecure Q1 Net Loss 4.1 Mln Zlotys
Brief: Molecure Says Its In-Consortium Project Selected For Funding By Medical Research Agency
Brief: Molecure To Sell 4.12 Mln Series K Shares and 2.0 Mln Existing Shares At 5 Zlotys/Shr
Brief: Molecure Starts ABB For Up to 4.12 Mln New Series K Shares And Up To 2.0 Mln Existing Shares
Brief: Molecure Signs Conditional Investment Agreement With MS Galleon And Szumowski Investments